BRIEF-Dermata Withdraws FDA Application for Xyngari, Shifts Focus to OTC Skin Care

Reuters
Sep 10
BRIEF-Dermata Withdraws FDA Application for Xyngari, Shifts Focus to OTC Skin Care

Sept 10 (Reuters) - Dermata Therapeutics Inc DRMA.O:

  • DERMATA THERAPEUTICS INC: HAS WITHDRAWN ITS INVESTIGATIONAL NEW DRUG APPLICATION FOR XYNGARI WITH U.S. FOOD AND DRUG ADMINISTRATION

  • DERMATA THERAPEUTICS : PLANS TO LAUNCH ITS INITIAL ACNE KIT IN MIDDLE OF 2026 WITH ADDITIONAL PRODUCT CANDIDATES ANTICIPATED TO FOLLOW

  • DERMATA THERAPEUTICS : STRATEGIC PIVOT TO PRIORITIZE DEVELOPMENT AND DISTRIBUTION OF OTC PHARMACEUTICAL DERMATOLOGY FOCUSED PRODUCTS

Source text: [ID:n0001493152-25-012952]

Further company coverage: DRMA.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10